390 related articles for article (PubMed ID: 33044876)
1. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
Marchand A; Kervarrec T; Bhatia S; Samimi M
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
[TBL] [Abstract][Full Text] [Related]
2. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Gaiser MR; Bongiorno M; Brownell I
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
[TBL] [Abstract][Full Text] [Related]
6. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Nghiem P; Bhatia S; Lipson EJ; Sharfman WH; Kudchadkar RR; Brohl AS; Friedlander PA; Daud A; Kluger HM; Reddy SA; Boulmay BC; Riker A; Burgess MA; Hanks BA; Olencki T; Kendra K; Church C; Akaike T; Ramchurren N; Shinohara MM; Salim B; Taube JM; Jensen E; Kalabis M; Fling SP; Homet Moreno B; Sharon E; Cheever MA; Topalian SL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879601
[TBL] [Abstract][Full Text] [Related]
7. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
8. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
9. Current concepts and approaches to merkel cell carcinoma.
Babadzhanov M; Doudican N; Wilken R; Stevenson M; Pavlick A; Carucci J
Arch Dermatol Res; 2021 Apr; 313(3):129-138. PubMed ID: 32666149
[TBL] [Abstract][Full Text] [Related]
10. Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.
LoPiccolo J; Schollenberger MD; Dakhil S; Rosner S; Ali O; Sharfman WH; Silk AW; Bhatia S; Lipson EJ
J Immunother Cancer; 2019 Jul; 7(1):170. PubMed ID: 31287031
[TBL] [Abstract][Full Text] [Related]
11. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
[TBL] [Abstract][Full Text] [Related]
12. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
Nghiem P; Bhatia S; Lipson EJ; Sharfman WH; Kudchadkar RR; Brohl AS; Friedlander PA; Daud A; Kluger HM; Reddy SA; Boulmay BC; Riker AI; Burgess MA; Hanks BA; Olencki T; Margolin K; Lundgren LM; Soni A; Ramchurren N; Church C; Park SY; Shinohara MM; Salim B; Taube JM; Bird SR; Ibrahim N; Fling SP; Homet Moreno B; Sharon E; Cheever MA; Topalian SL
J Clin Oncol; 2019 Mar; 37(9):693-702. PubMed ID: 30726175
[TBL] [Abstract][Full Text] [Related]
13. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
[TBL] [Abstract][Full Text] [Related]
14. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
15. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
16. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Nghiem PT; Bhatia S; Lipson EJ; Kudchadkar RR; Miller NJ; Annamalai L; Berry S; Chartash EK; Daud A; Fling SP; Friedlander PA; Kluger HM; Kohrt HE; Lundgren L; Margolin K; Mitchell A; Olencki T; Pardoll DM; Reddy SA; Shantha EM; Sharfman WH; Sharon E; Shemanski LR; Shinohara MM; Sunshine JC; Taube JM; Thompson JA; Townson SM; Yearley JH; Topalian SL; Cheever MA
N Engl J Med; 2016 Jun; 374(26):2542-52. PubMed ID: 27093365
[TBL] [Abstract][Full Text] [Related]
17. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
Zaremba A; Chorti E; Jockenhöfer F; Bolz S; Sirin S; Glas M; Becker JC; Ugurel S; Roesch A; Schadendorf D; Livingstone E; Hagenacker T; Zimmer L
J Immunother Cancer; 2019 May; 7(1):141. PubMed ID: 31142383
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Barkdull S; Brownell I
Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
[TBL] [Abstract][Full Text] [Related]
20. Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
Ricco G; Andrini E; Siepe G; Mosconi C; Ambrosini V; Ricci C; Casadei R; Campana D; Lamberti G
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
